Consistent with this, many studies have investigated the effects on cancer growth of ASCT2 inhibition with small molecule compounds such as V9302 (Schulte et al., 2018), l-γ-glutamyl-p-nitroanilide (GPNA) (Esslinger et al., 2005), and benzylserine (Grewer and Grabsch, 2004), and with ASCT2-specific monoclonal antibodies (Hara et al., 2020). Here, SLC1A5 is linked to cancer.